A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran

被引:30
|
作者
Zerehsaz, F
Salmanpour, R
Handjani, F
Ardehali, S
Panjehshahin, MR
Tabei, SZ
Tabatabaee, HR
机构
[1] Shiraz Univ Med Sci, Dept Dermatol, Shiraz, Iran
[2] Shiraz Univ Med Sci, Dept Parasitol & Mycol, Shiraz, Iran
[3] Shiraz Univ Med Sci, Dept Pharmacol, Shiraz, Iran
[4] Shiraz Univ Med Sci, Dept Pathol, Shiraz, Iran
[5] Shiraz Univ Med Sci, Dept Community Med, Shiraz, Iran
关键词
D O I
10.1046/j.1365-4362.1999.00727.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
A double-blind randomized clinical trial was undertaken to compare the efficacy of meglumine antimoniate solution (Glucantime), administered intramuscularly, with a topical herbal extract consisting of a pure extract mixture of Althaea rosa, Althaea officinalis, and members of the families Leguminosae, Faliaceae, Malvaceae, and Lythraceae (named Z-HE) on patients with Old World cutaneous leishmaniasis, The reason for undertaking such a study is that many patients fail to respond to the conventional treatment of cutaneous leishmaniasis (CL), the pentavalent antimonials. Many alternative treatment modalities have been proposed, and one such modality has been the use of herbal extracts applied topically to the lesions. Herbal remedies have been used for a long period of time in Iran for the treatment of many dermatoses, including CL; however, a systematic scientific evaluation of the efficacy of herbal extracts has rarely been performed. A total number of 171 patients who had been referred to the Cutaneous Leishmania Clinic in our center and who were diagnosed as having CL were included in the study. All patients underwent a complete clinical evaluation, and patients were excluded if they were pregnant or nursing or if they had serious concomitant diseases. A diagnosis of CL was based on positive smears from the lesions, and in some cases cultures and histopathologic studies were also performed. The duration of disease in all cases was less than 4 months. The patients were divided randomly into two treatment groups. In the first group (A), 86 patients were treated with the topical herbal extract Z-HE as a black paste applied to the lesions and covered by a dressing for five consecutive days, as well as with 0.5 mt of sterile normal saline used as a placebo and injected intramuscularly for 20 consecutive days. In the second group (B), 85 patients were treated with meglumine antimoniate (Glucantime), 15-20 mg/kg/day, as intramuscular injections for 20 consecutive days, as well as with a topical placebo which consisted of petrolatum mixed with charcoal powder and which was applied on the lesions as a black paste covered by a dressing for five consecutive days. Prior to the initiation of treatment with Z-HE, an animal toxicologic study was undertaken and the plant extract was declared safe to use in human clinical trials. Clinical evaluation was performed 6 weeks post-treatment, Complete cure was defined a clinical improvement with complete healing and re-epithelialization of the lesion(s), partial cure was defined as partial clinical improvement with reduction in infiltration, erythema, and size of the lesion(s), and failure was defined as the absence of any changes in the lesion(s) or progression and worsening of the lesion(s).
引用
收藏
页码:610 / 612
页数:3
相关论文
共 50 条
  • [1] A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran (vol 38, pg 610, 1999)
    Zerehsaz, F
    Salmanpour, R
    Handjani, F
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 1999, 38 (12) : 959 - 959
  • [2] A double-blind randomized clinical trial of a topical herbal extract (Z-he) vs. systemic meglumine antimonate
    Momeni, AZ
    Aminjavaheri, M
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2000, 39 (11) : 880 - 880
  • [3] Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru
    Miranda-Verástegui, C
    Llanos-Cuentas, A
    Arévalo, I
    Ward, BJ
    Matlashewski, G
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (10) : 1395 - 1403
  • [4] Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran
    Mohebali, M.
    Fotouhi, A.
    Hooshmand, B.
    Zarei, Z.
    Akhoundi, B.
    Rahnema, A.
    Razaghian, A. R.
    Kabir, M. J.
    Nadim, A.
    ACTA TROPICA, 2007, 103 (01) : 33 - 40
  • [5] A Randomized, Controlled, Noninferiority, Multicenter Trial of Systemic vs Intralesional Treatment With Meglumine Antimoniate for Cutaneous Leishmaniasis in Brazil
    Lyra, Marcelo R.
    Oliveira, Liliane F. A.
    Schubach, Armando O.
    Sampaio, Raimunda N. R.
    Rodrigues, Bruna C.
    Hueb, Marcia
    Cota, Glaucia
    Silva, Rosiana E.
    Francesconi, Fabio
    Pompilio, Mauricio A.
    Franca, Adriana O.
    Amato, Valdir S.
    Souza, Regina M.
    Oliveira, Raquel V. C.
    Valete, Claudia M.
    Pimentel, Maria I. F.
    CLINICAL INFECTIOUS DISEASES, 2023, 77 (04) : 574 - 582
  • [6] Dressings Combined with Injection of Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial
    Khatami, Alireza
    Talaee, Rezvan
    Rahshenas, Makan
    Khamesipour, Ali
    Mehryan, Pedram
    Tehrani, Sepideh
    Dowlati, Yahya
    Firooz, Alireza
    PLOS ONE, 2013, 8 (06):
  • [7] Use of topical rSm29 in combination with intravenous meglumine antimoniate in the treatment of cutaneous leishmaniasis: A randomized controlled trial
    Lago, Taina
    Peixoto, Fabio
    Mambelli, Fabio
    Carvalho, Lucas P.
    Guimaraes, Luiz Henrique
    Carvalho, Augusto M.
    Cardoso, Luciana
    Machado, Paulo R. L.
    Scott, Phillip
    Lago, Jamile
    Andrade, Juvana M.
    Fahel, Julia S.
    Oliveira, Sergio C.
    Carvalho, Edgar M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 147
  • [8] A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis
    Neves, Leandro Ourives
    Talhari, Anette Chrusciak
    Nunes Gadelha, Ellen Priscilla
    da Silva Junior, Roberto Moreira
    de Oliveira Guerra, Jorge Augusto
    de Lima Ferreira, Luiz Carlos
    Talhari, Sinesio
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2011, 86 (06) : 1092 - 1101
  • [9] Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran
    Iraji, F
    Sadeghinia, A
    ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2005, 99 (01): : 3 - 9
  • [10] Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial
    Javadi, Amir
    Khamesipour, Ali
    Ghoorchi, Mohammad
    Bahrami, Mahdieh
    Khatami, Alireza
    Sharifi, Iraj
    Eskandari, Seyed Ebrahim
    Fekri, Alireza
    Aflatoonian, Mohamad Reza
    Firooz, Alireza
    PLOS NEGLECTED TROPICAL DISEASES, 2022, 16 (07):